Litigation Details for Pharmacyclics LLC v. Hetero USA Inc. (D. Del. 2018)

« Back to Dashboard

Pharmacyclics LLC v. Hetero USA Inc. (D. Del. 2018)

Docket		Date Filed	2018-11-12
Court	District Court, D. Delaware	Date Terminated	2019-02-12
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,754,090; 9,296,753; 9,540,382; 9,713,617; 9,725,455
Link to Docket	External link to docket

Details for Pharmacyclics LLC v. Hetero USA Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-11-12				External link to document
2018-11-12	1		United States Patent Nos. 8,754,090 (“the ’090 Patent”); 9,296,753 (“the ’753 Patent”); 9,540,382 (“…(“the ’382 Patent”); 9,713,617 (“the ’617 Patent”); and 9,725,455 (“the ’455 Patent”). Case 1:18-cv… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…22. This civil action for patent infringement arises under the patent laws of the United States, including… THE ASSERTED PATENTS 37. The ’090 Patent, entitled “Use of Inhibitors of	External link to document
2018-11-12	14		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,754,090 B2; 9,296,753 B2; 9,540,382… 12 February 2019 1:18-cv-01778 835 Patent - Abbreviated New Drug Application(ANDA)	External link to document

Pharmacyclics LLC v. Hetero USA Inc. Litigation Summary and Patent Analysis

Last updated: August 15, 2026

Pharmacyclics LLC v. Hetero USA Inc., No. 1:18-cv-01778, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware concerning Hetero's proposed generic version of ibrutinib, marketed by Pharmacyclics and Janssen as Imbruvica. Pharmacyclics asserted patents covering ibrutinib compounds and therapeutic uses. The case ended without a publicly reported trial judgment on patent validity or infringement. Its commercial significance was the potential timing of Hetero's generic entry against a product with multi-billion-dollar annual sales.

What drug and ANDA were at issue in Pharmacyclics v. Hetero?

The litigation concerned ibrutinib, a Bruton tyrosine kinase inhibitor sold as Imbruvica.

Item	Detail
Brand	Imbruvica
Active ingredient	Ibrutinib
Brand developers	Pharmacyclics LLC and Janssen Biotech Inc.
Parent commercial organization	AbbVie acquired Pharmacyclics in 2015
Therapeutic class	Bruton tyrosine kinase inhibitor
Dosage forms	Capsules and tablets
Regulatory pathway	Hetero ANDA for generic ibrutinib
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01778
Statute	Hatch-Waxman Act, including 35 U.S.C. § 271(e)(2)

Hetero's ANDA certification challenged Orange Book-listed ibrutinib patents. Pharmacyclics responded by filing suit within the statutory 45-day period following receipt of Hetero's Paragraph IV notice. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination or other statutory exceptions.

What patents protected Imbruvica in the Hetero litigation?

The principal patents identified in the litigation were U.S. Patent Nos. 8,754,090 and 9,725,455. The patents were assigned to Pharmacyclics and were directed to different aspects of ibrutinib protection, including the compound and therapeutic use claims.

Patent	General subject matter	Role in case	Approximate statutory expiration
U.S. 8,754,090	Ibrutinib and related BTK inhibitor compounds	Asserted Orange Book patent	March 2032, subject to patent-term adjustment
U.S. 9,725,455	Therapeutic use of ibrutinib	Asserted Orange Book patent	March 2032, subject to patent-term adjustment

The precise enforceable expiration date depends on the patent-term adjustment printed on the issued patent and the applicable Orange Book listing. Patent expiration is separate from pediatric exclusivity, orphan-drug exclusivity, regulatory exclusivity, and any settlement-based launch date.

The case should not be treated as an adjudication of the entire Imbruvica patent estate. Other patents covering formulations, dosing regimens, combination therapy, crystalline forms, manufacturing methods, and later-approved indications may have remained relevant to generic launch analysis.

What were Pharmacyclics' infringement allegations?

Pharmacyclics brought a statutory patent-infringement action based on Hetero's submission of an ANDA seeking FDA approval to market generic ibrutinib. The asserted theory under Section 271(e)(2) treats the ANDA filing as an act of infringement for purposes of resolving patent disputes before commercial launch.

The case likely involved two principal infringement categories:

1. Direct infringement based on Hetero's proposed product satisfying composition or compound claims.
2. Induced or contributory infringement theories associated with Hetero's proposed labeling and use of ibrutinib for patented indications.

The composition claims were commercially important because a generic product containing ibrutinib could face broad exposure if the proposed active ingredient fell within the asserted claims. Method-of-use claims presented a narrower risk because generic labeling can sometimes be designed around patented indications, although FDA labeling requirements and induced-infringement principles can make such strategies difficult.

What defenses did Hetero raise?

Hetero's Paragraph IV position necessarily placed patent validity, enforceability, or noninfringement at issue. In a Hatch-Waxman case involving compound and method-of-use claims, the standard defenses generally include:

• Invalidity for anticipation under 35 U.S.C. § 102.
• Invalidity for obviousness under 35 U.S.C. § 103.
• Lack of infringement.
• Failure to satisfy written-description or enablement requirements under 35 U.S.C. § 112.
• Potential unenforceability defenses, including inequitable conduct if supported by the record.

A Paragraph IV certification is an ANDA applicant's legal assertion that the listed patent is invalid, unenforceable, or will not be infringed. It is not a court finding that the patent is invalid. The same applies to the brand company's complaint: filing suit does not establish infringement.

What was the procedural history of the case?

Case filing and Hatch-Waxman stay

Pharmacyclics filed the complaint in the District of Delaware in 2018 after Hetero notified the patent holder of its Paragraph IV certifications. The filing initiated the statutory patent dispute before FDA approval of Hetero's ANDA.

Procedural event	Significance
Paragraph IV notice	Hetero alleged that listed patents were invalid, unenforceable, or not infringed
Complaint filed in 2018	Pharmacyclics asserted patent infringement under the Hatch-Waxman framework
Statutory stay	FDA approval was generally subject to the 30-month stay
Discovery and claim construction	The parties would have developed technical and legal positions on compound and use claims
Case termination	The action ended without a reported merits decision after trial

The public litigation record does not establish a Federal Circuit merits ruling arising from this civil action. There is no reported decision in the case holding the asserted patents valid and infringed, or invalid and not infringed.

Did the case go to trial?

No publicly reported trial judgment resolved the asserted patents in Pharmacyclics v. Hetero. The case terminated before a reported merits adjudication. That outcome limits the precedential value of the docket.

The absence of a trial decision also means that the litigation did not publicly determine:

• Whether Hetero's ANDA product infringed the asserted claims.
• Whether the 090 patent survived Hetero's invalidity arguments.
• Whether the 455 patent's method-of-use claims were enforceable against Hetero's proposed labeling.
• Whether any claim construction position would have controlled future generic litigation.

Was there a settlement agreement between Pharmacyclics and Hetero?

The case ended without a publicly reported merits ruling, consistent with resolution through dismissal or settlement. The operative settlement terms, including any agreed generic launch date, license scope, authorized-generic provisions, or payment terms, are not established by the publicly available court judgment record.

In pharmaceutical patent settlements, the commercially material terms often include:

• A license date for generic entry.
• Restrictions on launch by dosage form or indication.
• A covenant not to sue.
• An agreement governing patent challenges to later-issued patents.
• A no-acceleration provision tied to other generic entrants.
• An authorized-generic or supply arrangement.
• FTC or DOJ review under the Medicare Prescription Drug, Improvement, and Modernization Act.

A dismissal alone does not prove that Hetero received an unrestricted license. It also does not prove that Hetero abandoned its ANDA. The FDA's final approval status, the settlement agreement, and any confidential commercial provisions must be analyzed separately.

What is the Orange Book status of Imbruvica?

The Orange Book listed multiple patents associated with Imbruvica products and indications. The patents asserted against Hetero were part of a larger estate rather than the entire protection profile for ibrutinib.

Compound patents

Compound patents generally provide the strongest generic-entry barrier because a conventional generic product uses the same active pharmaceutical ingredient. If a valid compound claim covers ibrutinib and the ANDA product contains ibrutinib, a noninfringement position is difficult.

Method-of-use patents

Method-of-use patents cover treatment of specified diseases, patient populations, dosing schedules, or combinations. Their value depends on:

• The scope of the FDA-approved label.
• Whether the patented use is required by the label.
• Whether the generic applicant can use a skinny label.
• Whether the brand can establish induced infringement.
• Whether substantial noninfringing uses remain.

Formulation patents

Ibrutinib patent analysis also requires review of dosage-form and formulation patents. A generic applicant may avoid some formulation claims by using a different excipient system, particle size, solid form, coating, capsule, tablet process, or manufacturing route. Formulation patents therefore tend to create narrower barriers than a broad active-ingredient patent, although they can delay approval when they cover the only commercially practical product design.

When does Imbruvica lose exclusivity?

Imbruvica's market exclusivity is layered.

Exclusivity category	Effect
New chemical entity exclusivity	Prevented ANDA submission for the statutory period after initial approval
Orphan-drug exclusivity	Applied to qualifying disease indications and barred approval of the same drug for the same indication during the exclusivity period
Patent exclusivity	Depends on each patent's claims, expiration, and enforceability
Pediatric exclusivity	Can add six months to certain listed patents or exclusivities if awarded
Settlement-based license	Can establish a launch date earlier or later than patent expiration

The key patent dates for the two patents associated with this litigation fall in the March 2032 period, subject to the exact patent-term adjustment and any applicable pediatric extension. A generic launch before that date would ordinarily require one of four outcomes: a successful invalidity or noninfringement result, a license from the patent holder, an enforceable settlement right, or a change in the relevant patent or regulatory landscape.

What generic entry risks existed for Pharmacyclics?

The risk profile differed by patent type.

Risk factor	Assessment
Compound coverage	High potential barrier if the 090 claims covered Hetero's ibrutinib product
Method-of-use coverage	Dependent on Hetero's final labeling and the patented indications
Formulation design-around	Potentially available if non-infringing dosage-form alternatives existed
Patent expiration	The principal asserted patents extended into 2032
ANDA litigation	Delayed FDA approval during the statutory stay unless the stay ended earlier
Settlement risk	Could create an authorized launch date before patent expiration
Later-issued patents	Could create separate litigation after resolution of the 2018 case

For Pharmacyclics, the most material risk was not necessarily immediate full-market generic substitution. A settlement or court decision could have allowed entry for selected indications, dosage forms, or dates. Such partial entry can reduce brand pricing power before total patent expiry.

Which companies challenged Imbruvica patents?

Hetero was one of several generic or potential generic manufacturers associated with ibrutinib patent challenges. Other challengers and defendants in separate Imbruvica litigation have included generic pharmaceutical companies seeking approval for ibrutinib products. Each action must be evaluated independently because:

• Different ANDAs may use different formulations.
• Paragraph IV certifications may target different patents.
• Settlements may contain different launch dates.
• One defendant's judgment does not automatically resolve another defendant's ANDA.
• A settlement with one applicant may affect commercial timing for others through most-favored-entry or acceleration provisions.

The Hetero case therefore provides a company-specific record, not a complete resolution of all generic challenges to Imbruvica.

How strong was the Imbruvica patent estate?

The estate was commercially strong during the period covered by the litigation because it combined long-dated patent protection with a high-value active ingredient and multiple approved hematologic indications.

Strengths

The strongest feature was compound-level protection. A valid compound patent can block ordinary generic substitution regardless of which disease indication appears on the label. The estate also included method-of-use and product-specific protections, creating additional litigation positions.

The FDA-approved indication set increased the value of method-of-use patents. Imbruvica was approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and chronic graft-versus-host disease, among other uses over time.[1]

Constraints

The estate also faced standard pharmaceutical patent risks. Compound claims can be attacked through prior-art and obviousness theories. Method-of-use claims can be narrowed through label design. Formulation claims may be designed around. Later-issued patents may face written-description, enablement, obviousness-type double-patenting, and prosecution-history challenges.

The lack of a merits decision in the Hetero case means the public record does not assign a judicially tested validity score to the asserted patents.

What was the revenue exposure from Hetero's proposed generic?

Imbruvica generated multi-billion-dollar annual revenue for AbbVie and its collaboration partners. AbbVie reported Imbruvica net revenues of approximately $4.6 billion in 2023, with revenue declining from prior peaks as competition and market factors affected the product.[2]

Hetero's individual launch would not necessarily have captured the entire market. The economic effect would have depended on:

• Whether Hetero launched alone or alongside other ANDA applicants.
• Whether it entered with all indications or a skinny label.
• The number of approved generic suppliers.
• Generic price erosion.
• Contracting and formulary substitution.
• The availability of authorized generic supply.
• The timing of entry relative to the 2032 patent horizon.

The case's strategic value was therefore tied to entry sequencing. The first generic entrant can obtain materially better economics than later entrants, while the brand can face rapid erosion once multiple suppliers receive approval.

How does this case compare with a patent judgment?

Pharmacyclics v. Hetero is materially different from a case ending in a bench-trial opinion.

Issue	Hetero litigation outcome	Trial judgment
Validity	Not adjudicated in a reported merits decision	Determined by the court
Infringement	Not adjudicated in a reported merits decision	Determined claim by claim
Launch date	Governed by settlement, dismissal terms, patents, and FDA status	Governed by judgment and applicable injunction
Precedent	Limited	Potentially persuasive or precedential after appeal
Portfolio effect	Defendant-specific	May affect broader litigation depending on claim construction and appellate rulings

The case should be used as a settlement and market-entry indicator, not as proof that the asserted patents were upheld.

What is the current litigation significance?

The principal value of the docket is historical and commercial:

1. It confirms that Hetero pursued an ANDA-based challenge to Imbruvica protection.
2. It identifies the 090 and 455 patents as important patents in that dispute.
3. It shows that the matter did not produce a reported trial decision.
4. It indicates that generic entry analysis must account for settlement terms and the broader Orange Book estate.
5. It does not resolve the validity or enforceability of every Imbruvica patent.

Any current launch-risk assessment should distinguish the Hetero docket from later patents, later ANDAs, FDA approval actions, and separate litigation involving other generic manufacturers.

Key Takeaways

• Pharmacyclics LLC v. Hetero USA Inc., No. 1:18-cv-01778, was a Hatch-Waxman case over generic ibrutinib.
• The litigation centered on U.S. Patent Nos. 8,754,090 and 9,725,455.
• The patents had expiration dates in the March 2032 period, subject to patent-term adjustment and any applicable extensions.
• The case ended without a publicly reported trial decision on validity or infringement.
• The record should not be treated as a judicial confirmation of the patent estate's strength.
• Compound protection presented the principal generic-entry barrier.
• Method-of-use and formulation patents created additional, narrower litigation risks.
• Imbruvica's commercial exposure was substantial because annual sales exceeded $4 billion in the relevant period.
• The ultimate generic launch date depends on the settlement record, Orange Book status, FDA action, later-issued patents, and other ANDA litigation.

FAQs About Pharmacyclics v. Hetero

Did Hetero receive FDA approval for generic ibrutinib?

The civil docket alone does not establish the date or scope of any FDA approval. FDA approval must be confirmed through the agency's ANDA records and the Orange Book.

Did Pharmacyclics win the case against Hetero?

There was no publicly reported merits judgment establishing that Pharmacyclics won on validity and infringement. The case ended without a reported trial decision.

Can a generic launch before the 2032 patent expiration?

Yes, but only through a successful patent challenge, a license or settlement right, a noninfringing product and labeling strategy, or another legally effective pathway.

Did the Hetero case invalidate Imbruvica patents?

No reported decision from this action invalidated the asserted patents. The absence of a merits ruling leaves the patents' validity unresolved in this docket.

Are Imbruvica's method-of-use patents as strong as its compound patents?

Generally, no. Compound patents can cover the active ingredient across indications, while method-of-use patents depend on the patented indication, label language, and proof of infringement. Their commercial strength can still be significant when the patented use is central to the FDA-approved label.

References

1. U.S. Food and Drug Administration. (2024). Imbruvica (ibrutinib) prescribing information. FDA.
2. AbbVie Inc. (2024). 2023 annual report. AbbVie.
3. Pharmacyclics LLC v. Hetero USA Inc., No. 1:18-cv-01778, U.S. District Court for the District of Delaware. (2018-2020). Court docket and pleadings.
4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,754,090: Substituted pyrazolo[3,4-d]pyrimidines as inhibitors of Bruton's tyrosine kinase.
5. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,725,455.